The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
Feature|Videos|September 11, 2024
Grace: Your API CDMO Partner of Choice
Bob Hughes (Research Fellow, Grace) and Brian Graves (Global Business Manager, Fine Chemicals, Grace) explain how Grace's experience as a CDMO can help customers from the lab to full-scale production.
Advertisement
Bob Hughes and Brian Graves sat down with Pharmaceutical Technology to highlight key elements of working alongside Grace. Learn more about:
- How with 40 years of experience in the CDMO space, Grace is a collaborative partner with their customers throughout the entire project, from the lab to commercial-scale production
- Grace's well-established, systematic processes for executing your next small molecule API project
- Grace’s Fine Chemical Manufacturing Services (FCMS) and the technical expertise & operational capabilities to support your next project
Advertisement
Related to this article
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement